Marnin Merrick, MD
Hematology & Oncology · New Orleans, LANPI 1114132818
Payments from drug & device makers
Across 23 payments — averaging $116.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Athenex Pharmaceutical Division, LLC$150
- Angiodynamics, Inc.$142
- GSK$135
- Puma Biotechnology, Inc.$121
- Jazz Pharmaceuticals Inc.$102
- plus $579 from 13 others
What the payments were for
- Consulting fees$1,68563%
- Speaking & faculty fees$1506%
- Food & beverage$84532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $1,450 |
| Athenex Pharmaceutical Division, LLC | 1 | $150 |
| Angiodynamics, Inc. | 1 | $142 |
| GSK | 1 | $135 |
| Puma Biotechnology, Inc. | 1 | $121 |
| Jazz Pharmaceuticals Inc. | 1 | $102 |
| Cardinal Health 110 LLC | 1 | $100 |
| Olympus America Inc. | 1 | $99 |
| Reflexion Medical, Inc. | 3 | $75 |
| Scilex Pharmaceuticals Inc. | 1 | $73 |
| GRT US Holding, Inc. | 1 | $62 |
| Blue Earth Diagnostics | 1 | $37 |
| Boston Scientific | 1 | $36 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Merck | 1 | $14 |
| Dova Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$925
- TAGRISSO$525
- Oral Paclitaxel$150
- Encequidar$150
- Nanoknife$142
- Nerlynx$121
- ZEPZELCA$102
How this compares
$2,680 in reported general payments places this provider in the 25th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Orleans
- Marc MatranaNew Orleans$4.6M
- Pedro BarataNew Orleans$4.2M
- Carter DavisNew Orleans$1.6M
- Maissaa JanbainNew Orleans$1.5M
- Lingling duNew Orleans$1.2M
- John ColeNew Orleans$896K
- Cindy LeissingerNew Orleans$432K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.